Summary
Hodgkin’s disease is curable in the majority of patients, although a proportion of patients are resistant to or relapse after initial therapy. High-dose therapy with autologous stem cell support has become the standard salvage therapy for patients failing chemotherapy, but there have been reports of a high incidence of myelodysplasia/acute myeloid leukaemia (MDS/AML) following such treatment. Patients who receive such therapy form a selected group, however, who have already been subjected to other leukaemogenic factors, such as treatment with alkylating agents. In order to ascertain the true risk of MDS/AML, comparison must be made with other patients subjected to the same risks but not undergoing transplantation. We report a retrospective comparative study of 4576 patients with Hodgkin’s disease from the BNLI and UCLH Hodgkin’s databases, which includes 595 patients who have received a transplant. Statistical analysis including Cox’s proportional hazards multivariate regression model with time-dependent covariates was employed. This analysis reveals that the risk of developing MDS/AML was dominated by three factors, namely quantity of prior therapy (relative risk [RR] 2.01, 95% confidence intervals [CI] 1.49–2.71, for each treatment block, P < 0.0001) and whether the patient had been exposed to MOPP (RR 3.61, 95% CI 1.64–7.95, P = 0.0009) or lomustine chemotherapy (RR 4.53, 95% CI 1.96–10.44, P = 0.001). Following adjustment for these factors in the multivariate model the relative risk associated with transplantation was 1.83 (95% CI 0.66–5.11, P = 0.25). This study provides no evidence of a significantly increased risk of MDS/AML associated with BEAM therapy and autologous transplantation in Hodgkin’s disease. Concern over MDS/AML should not mitigate against the timely use of this treatment modality.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Andre, M, Henry-Amar, M, Blaise, D, Colombat, P, Fleury, J, Milpied, N, Cahn, J-Y, Pico, J-L, Bastion, Y, Kuentz, M, Nedellec, G, Attal, M, Ferme, C & Gisselbrecht, C (1998). Treatment-related deaths and second cancer risk after autologous stem cell transplantation for Hodgkin’s disease. Blood 92: 1933–1940.
Carella, AM, Carlier, P, Congiu, A, Occhini, D, Nati, S, Santini, G, Pierluigi, D, Giordano, D, Bacigalupo, A & Damasio, E (1991). Autologous bone marrow transplantation as adjuvant treatment for high risk Hodgkin’s disease in first complete remission after MOPP/ABVD protocol. Bone Marrow Transplant 8: 99–103.
Chopra, R, McMillan, AK, Linch, DC, Yuklea, S, Taghipour, G, Pearce, R, Paterson, K & Goldstone, AH (1993). The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin’s disease. A single-centre eight-year study of 155 patients. Blood 81: 1137–1145.
Cox, DR (1972). Regression models and life tables. J Royal Stat Soc, (B)34: 187–220.
Darrington, DL, Vose, JM, Anderson, JR, Bierman, PJ, Bishop, MR, Chan, WC, Morris, ME, Reed, EC, Sanger, WG, Tarantolo, SR, Weisenberger, DD, Kessinger, A & Armitage, JO (1994). Incidence and characterisation of secondary myelodysplastic syndrome and acute myelogenous leukaemia following high dose chemoradiotherapy and autologous stem cell transplantation for lymphoid malignancies. J Clin Oncol 12: 2527–2534.
Devereux, S, Selassie, TG, Vaughan Hudson, G, Vaughan Hudson, B & Linch, DC (1990). Leukaemia complicating treatment for Hodgkin’s disease: the experience of the British National Lymphoma Investigation. Br Med J 301: 1077–1080.
Devereux, S (1991). Therapy-associated leukaemia. Blood Rev 5: 138–145.
Gale, RE, Bunch, C, Moir, DJ, Patterson, KP, Goldstone, AH & Linch, DC (1996). Demonstration of developing myelodysplasia/acute myeloid leukaemia in haematologically normal patients after high dose chemotherapy and autologous bone marrow transplantation using X-chromosome inactivation patterns. Br J Haematol 93: 53–58.
Glicksman, AS, Pajak, TF, Gottlieb, A, Nissen, N, Stutzman, L & Cooper, MR (1982). Second malignant neoplasms in patients successfully treated for Hodgkin’s disease: a Cancer and Leukaemia Group B study. Cancer Treat Rep 66: 1035–1044.
Gregory, W (1988). Adjusting survival curves for imbalances in prognostic factors. Br J Cancer 58: 202–204.
Harrison, CN, Vaughan Hudson, G, Perry, A, Anderson, L, MacMillan, A, Devereux, S, Goldstone, AH & Linch, DC (1996). BEAM and ABMT/PBSCT may reduce the risk of secondary leukaemia in Hodgkin’s disease: a case control analysis with the BNLI database (Abstract). Blood 88: 262a.
Jagannath, S, Armitage, JO, Dicke, KA, Tucker, SL, Velasquez, WS, Smith, K, Vaughan, WP, Kessinger, A, Horwitz, W, Hagemeister, FB, McLaughlin, P, Cabanillas, F & Spitzer, G (1989). Prognostic factors for response and survival after high dose cyclophosphamide, carmustine and etoposide with autologous bone marrow transplantation for relapsed Hodgkin’s disease. J Clin Oncol 7: 179–185.
Kaplan, EL & Meier, P (1958). Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481.
Khwaja, A, Linch, DC, Goldstone, AH, Chopra, R, Marcus, RE, Wimperis, JZ, Russell, NH, Haynes, AP, Milligan, DW, Leyland, MJ, Winfield, DA, Hancock, BW, Newland, A, Durrant, ST, Devereux, S, Roitt, S, Collins, S & Vaughan Hudson, G (1992). Recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a British National Lymphoma Investigation double-blind, placebo-controlled trial. Br J Haematol 82: 317–323.
Lacher, MJ & Susman, LN (1963). Leukaemia and Hodgkin’s disease. Ann Intern Med 59: 369–378.
Linch, DC, Winfield, D, Goldstone, AH, Moir, D, Hancock, B, McMillan, A, Chopra, R, Milligan, D & Vaughan Hudson, G (1993). Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet 341: 1051–1054.
Marolleau, JP, Brice, P, Morel, P & Gisselbrecht, C (1993). Secondary acute myeloid leukaemia after bone marrow transplantation for malignant lymphomas (letter). J Clin Oncol 11: 590–591.
Miller, JS, Arthur, DC, Litz, CE, Neglia, JP, Miller, WJ & Weisdorf, DJ (1994). Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy. Blood 83: 3780–3786.
Mills, W, Strang, J, Goldstone, AH & Linch, DC (1995). Dose intensification of etoposide in the BEAM ABMT protocol for malignant lymphoma. Leuk Lymphoma 17: 263–270.
Pedersen-Bjergaard, J & Larsen, SO (1982). Incidence of acute nonlymphocytic leukaemia. Preleukaemia and acute myeloproliferative syndrome up to 10 years after treatment of Hodgkin’s disease. N Engl J Med 307: 965–971.
Pedersen-Bjergaard-J, Specht, L, Larsen, SO, Ersboll, J, Struck, J, Hansen, MM, Hansen, HH & Nissen, NI (1987). Risk of therapy-related leukaemia and preleukaemia after Hodgkin’s disease: relation to age, cumulative dose of alkylating agents and time from chemotherapy. Lancet II, (1): 83–88.
Pedersen-Bjergaard, J, Pedersen, M, Myhre, J & Geisler, C (1997). High risk of therapy-related leukaemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphomas is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure. Leukaemia 11: 1654–1660.
Peto, R, Pike, MC, Armitage, P, Breslow, NE, Cox, DR, Howard, SV, Mantel, N, McPherson, K, Peto, J & Smith, PG (1977). Design and analysis of randomised clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35: 1–39.
Reece, DE, Barnett, MJ, Connors, JM, Fairey, RN, Fay, JW, Greer, JP, Herzig, GP, Herzig, RH, Klingemann, HG, LeMaisre, CF, O’Reilly, SE, Shepherd, JD, Spinelli, JJ, Voss, NJ, Wolff, SN & Philips, GL (1991). Intensive chemotherapy with cyclophosphamide, carmustine and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin’s disease. J Clin Oncol 9: 1871–1879.
Stone, RM (1994). Myelodysplastic syndrome after autologous transplantation for lymphoma: the price of progress?. Blood 83: 3437–3440.
Stone, RM, Neuberg, D, Soiffer, R, Takvorian, T, Whelan, M, Rabinowe, S, Aster, JC, Leavitt, P, Mauch, P, Freedman, AS & Nadler, LM (1994). Myelodysplastic syndrome following autologous bone marrow transplantation for non-Hodgkin’s lymphoma. J Clin Oncol 12: 2535–2542.
Swerdlow, AJ, Douglas, AJ, Vaughan Hudson, G, Vaughan Hudson, B & MacLennan, KA (1993). Risk of second primary cancer after Hodgkin’s disease in patients in the British National Lymphoma Investigation: relationships to host factors, histology, and stage of Hodgkin’s disease and splenectomy. Br J Cancer 68: 1006–1011.
Traweek, ST, Slovak, ML, Nademanee, AP, Brynes, RK, Niland, JC & Forman, SJ (1994). Clonal karyotypic haematopoietic cell abnormalities occurring after autologous bone marrow transplantation for Hodgkin’s disease and non-Hodgkin’s lymphoma. Blood 84: 957–963.
Tucker, MA, Coleman, CN, Cox, RS, Varghese, A & Rosenberg, SA (1988). Risk of second cancers after treatment for Hodgkin’s disease. N Engl J Med 318: 76–81.
Wheeler, C, Antin, JH, Churchill, W, Come, SE, Smith, BR, Bubley, GJ, Rosenthal, DS, Rappaport, JM, Ault, KA, Schnipper, LE & Eder, JP (1990). Cyclophosphamide, carmustine and etoposide with autologous bone marrow transplantation in refractory Hodgkin’s disease and non-Hodgkin’s lymphoma: a dose finding study. J Clin Oncol 8: 648–656.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Harrison, C., Gregory, W., Hudson, G. et al. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin’s disease is unlikely to be associated with a major increased risk of secondary MDS/AML. Br J Cancer 81, 476–483 (1999). https://doi.org/10.1038/sj.bjc.6690718
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690718
Keywords
This article is cited by
-
Second Malignancies after Hematopoietic Stem Cell Transplantation
Current Treatment Options in Oncology (2018)
-
Stammzelltransplantation bei Multipler Sklerose
Der Nervenarzt (2015)
-
Does autologous transplantation directly increase the risk of secondary leukemia in lymphoma patients?
Bone Marrow Transplantation (2007)
-
Primary multifocal osseous Hodgkin disease: a case report and review of the literature
Journal of Cancer Research and Clinical Oncology (2005)
-
Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma
Bone Marrow Transplantation (2003)